Open AccessNew Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections
Author(s) -
Burcu Isler,
Yohei Doi,
Robert A. Bonomo,
David L. Paterson
Publication year - 2018
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01110-18
Subject(s) - acinetobacter baumannii , acinetobacter , carbapenem , pathogen , medicine , intensive care medicine , microbiology and biotechnology , biology , antibiotics , pseudomonas aeruginosa , bacteria , genetics
Carbapenem-resistantAcinetobacter baumannii (CRAB) is a perilous nosocomial pathogen causing substantial morbidity and mortality. Current treatment options for CRAB are limited and suffer from pharmacokinetic limitations, such as high toxicity and low plasma levels.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom